It was a pleasure to meet with Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA) to discuss a phase 3 study investigating oteseconazole in the treatment of recurrent vulvovaginal candidiasis.
The abstract entitled: ‘Susceptibility Testing of Oteseconazole (VT-1161) Against Clinical Isolates from Phase 3 Clinical Studies in Subjects with Recurrent Vulvovaginal Candidiasis‘ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
- What is the mechanism of action of oteseconazole? (0:05)
- What are the aims, and design of the phase 3 oteseconazole study? (1:05)
- What were the efficacy and safety findings of this study? (3:13)
- What questions remain unanswered about the use of oteseconazole in VVC and what future studies are planned? (5:26)
Disclosures: Mahmoud Ghannoum is contracted to conduct research from Mycovia pharmaceuticals, Scynexis, Amplyx Pharma, Gilead and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
Share this Video
Related Videos In Bacterial and Fungal Infections
Jinhee Jo, IDWeek 2021: Global Surveillance of Clostridioides difficile
It was a pleasure to meet with Dr Jinhee Jo (Department of Pharmacy Practice and Translational Research, University of Houston, Houston, TX, USA) to discuss her study investigating the understanding of how C. Difficile is transmitted, and who it affects. The abstract entitled: ‘Global Surveillance of Clostridioides difficile Demonstrates High Prevalence in Non-Healthcare Settings’ was […]
Kevin Garey, IDWeek 2021: Health-related Quality of Life Findings from the ECOSPOR Phase 3 Trial
It was a pleasure to meet with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the results from the ECOSPOR phase 3 trial, and how SER-109 impacts patients’ health-related quality of life. Watch Part 1 of this interview here. The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic […]
Kevin Garey, IDWeek 2021: Limitations of Current Treatment Approaches for Recurrent C difficile Infections
We had the great pleasure of meeting with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the health burden of C difficile infections, and the limitations of current treatment approaches. Watch Part 2 of the interview here. The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic SER-109 on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!